Biogen Closing Gap On Amevive Reimbursement: Pre-Authorization At 30%
Executive Summary
The percentage of Amevive patients needing prior authorization for the psoriasis biologic has shrunk to 30%, Biogen Idec CEO Jim Mullen told investors Jan. 12 at the J.P. Morgan health care cconference in San Francisco
You may also be interested in...
Zevalin Price Negotiations Will Be Model For Medicare Part B, Scully Says
Idec's experience securing Medicare reimbursement for Zevalin should be considered the model for how coverage decisions will work for new products once Part B payment reforms are implemented in 2005, former CMS Administrator Tom Scully said
J&J Procrit Medicare Reimbursement Will Be 87% Of AWP Under Final Rule
Johnson & Johnson's Procrit will be reimbursed at 87% of average wholesale price under Medicare Part B in 2004, two percentage points higher than most drugs
Biogen Wants To Reduce Amevive Copay, Adds Pharmacy Distribution
Biogen is pursuing initiatives to reduce the copay burden for patients taking the psoriasis agent Amevive